29 Defining materiality Engaging with our key stakeholders is essential to build trust and to understand their needs. We seek to listen to them, know how we can address their concerns, and develop solutions for significant issues. 1. Identifying key topics from the sustainability context The sustainability context for CDMOs highlights the need for flexible, responsive operations and technically superior solutions to enable pharmaceutical companies to pursue innovation to serve patients better. The need is to reach the market faster by de-risking discovery, development, and manufacturing in the NCE development value chain while focusing on meeting and exceeding quality, safety, and environmental standards as pre-requisites. CDMOs are expected to be environmentally responsible as pharmaceutical companies gather pace for climate change action in their own and their supplier organizations. Besides, CDMOs also need to focus on people, infrastructure, automation, and technical capabilities, to accelerate services and enable pharmaceutical companies sustain better drug commercialization with new technologies and approaches. With this background, we undertook the process of identifying key topics, also integrating findings from research of sector-specific reports, review of GRI standards, and sustainability reports of pharmaceutical companies and inputs received from internal stakeholders. Our process of carrying out stakeholder engagement and arriving at material focus areas is presented here: 1 Identifying key topics that have significant organizational impact 2Identifying key stakeholders 3Conducting stakeholder interviews to gather feedback on key topics 4Materiality assessment
RkJQdWJsaXNoZXIy MTIwMDc4NQ==